Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 279Carboplatin 214Cisplatin 145Gemcitabine 144Paclitaxel 142Bevacizumab 115Pemetrexed 112Docetaxel 100Oxaliplatin 78Dexamethasone 77durvalumab 76Fluorouracil 76atezolizumab 75Nivolumab 74Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 68Cetuximab 63Capecitabine 63Injections 61Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 49venetoclax 43Prednisone 43Irinotecan 42enzalutamide 39Letrozole 39tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × serabelisib × 90 days × Clear all
NCT05300048 2026-04-30

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Faeth Therapeutics

Phase 1 Terminated
34 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT07558733 2026-04-30

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Faeth Therapeutics

Phase 1/2 Recruiting
32 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡